Wuxi Bio to Sell Vaccine Facility to Merck

China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict business for Chinese biotech companies.
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
Merck to buy WuXi Biologics' Irish vaccine facility for $500 million
WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland to MSD International, a subsidiary of Merck & Co. for approximately $500 million.
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi AppTec are planning to sell some of their operations,
Merck to buy vaccine plant from WuXi Biologics: report
WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract research,
Merck says its HPV vaccine for men was approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Unpacking the Latest Options Trading Trends in Merck & Co
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Truist Financial downgrades Merck & Company (MRK) to a Hold
Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...
devdiscourse5h
Merck's HPV Vaccine Gains Ground in China
U.S. drugmaker Merck & Co has received approval in China for its HPV vaccine's use in males, expanding its market reach despite earlier weak sales in the region. This move marks a potential growth ...
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
Zacks.com on MSN1d
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.
devdiscourse6h
Merck's HPV Vaccine Gains Approval in China for Men
Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending ...